On April 29, 2013 the registrant filed, and on May 20, 2013 the registrant amended (on a pre-effective basis), a Registration Statement on Form S-1 (Registration No. 333-188211) with the Securities and Exchange Commission, or the SEC, which was declared effective by the SEC on May 24, 2013 (as amended, the Registration Statement). This Post-Effective Amendment No. 1 to Form S-1, or this Post-Effective Amendment, is being filed by the registrant pursuant to the undertakings in Item 17 of the Registration Statement to update and supplement the information contained in the Registration Statement to include the information contained in the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2013 (the Annual Report) that was filed with the SEC on March 27, 2014 and, in some cases, to reflect disclosure as of and through a more recent practicable date. No additional securities are being registered under this Post-Effective Amendment. All applicable SEC registration fees were paid at the time of the filing of the original Registration Statement.
No but there are some revenue issues. How did the company have about a 70% CMS reimbursement rate increase for Galectin-3 effective 2014 but no increase in revenues even when accounting for lost revenues due to the weather? Company bragged about the increase on conference call but no analyst asked how come no increase in revenues. The only thing that improved was the cost cutting from same quarter last year. The point being is that it all sounds nice, but no positive result on revenues since same time last year. Hope they are not losing big on this market due to competitors who can deliver the science more cost effective. That is the disadvantage these small companies have.
But it is not a new assay. BGM Galectin-3 Test already 510(k) cleared and studies were submitted with the automated Galectin-3 assay 510(K) that showed measurement values obtained with the automated Galectin-3 assay to be in excellent agreement with those obtained with the BGM Galectin-3 Test (Reference Method).
Call your broker since they are the ones doing it and ask them to explain what they are doing.
Jess, this is a different company than a year ago. Earnings per share were -.18 and -.13 when this stock traded to its low of .55. Last earnings per share was -.08. Stock dilution is factored in PPS. Price targets are not set by insider buying and what a stock traded to last year. This stock bounced around from .55 to .76 until we got some good news. FDA speculative approval is not factored in current price. I doubt we take any hit or very little at the .90 price range. Current earnings support current evaluation.
I agree. These guys know what they are doing. The higher the price the more money they can raise. On the lasy CC they also said they would have sales force doubled by end of 2nd quarter, also. Coincidence?? They like to issue more shares on pops.
The Abbott Architect automated Galectin-3 immunoassay has been in use in Europe for over a year now. The current BGMD Galectine is already FDA cleared. Several studies have shown automated version just as effective as current BGMD Galectine. This should be easy for FDA. It is not like it is a totally new immunoassay with nothing to compare it to. Should hear something within 6 weeks a latest. IMHO
I have no idea what you are talking about. The delisting process is set in motion when a company trades for 30 consecutive "business days" under one dollar. How many consecutive days trading under a 1 as of July 23? None. Then they get 180 calendar days to fix it not counting appeals.
They have done it of late no earlier than 7 days before earnings. Hear whispers of 13 and 14th. Look for it around 6th or 7th.
I see how you can get the 860s on reves due to sales upon researching prior earnings. How did U get to the 1.2? I know they plan on having double sales force by end of 2Q 2014 (10 total). You believe they hired all five at beginning and the increase amount is due to the five or they hired some during the quarter and the rest after and the increase was due to that? Do you know how much one of the salespersons can bring in revenue and how much they will cost the company in total expenses/operating costs?
Say we meet EPS of -.06 on earnings for 2nd Quarter 2014, which would be same EPS for 4th Quarter 2013 and better than -.08 EPS for 1st Quarter 2014 and way better than -.18 same time last year.
Shouldn't the stock prise rise even if the analyst is looking for 1.4 million in revenue 2nd Quarter 2014 and we only get say 865,000?
Seems like the Company is delivering ultimate result just through cost cutting instead of aggressive spending to increase revenues.
Seems like the analyst estimates are based on a $2.00 stock and not one trading at .90.
It appears that the Company was only concerned about releasing news to keep the stock elevated until they did the offering. Also, revenues were estimated to be 1.3 million last quarter based on that CMS rate increase effective January 1, 2014. Howevere, they came in at 739,000. Estimates are now 1.4 million this quarter based on that CMS rate increase for which there has been mysteriously no increase in revenues so far.
Who knows. It usually comes by the time it seems everyone is throwing in the towel. I know some people who have been in RNN since 1-1.50 range waiting on that partnership news due midyear. It is all a question of timing, patience, and pain tolerance with these spec bios. GLTA
NIce find. It was actually changed in August 2014 from recruiting to completed study along with all relevant updated information. It appears to me it was left open just in case FDA needed some further testing results. Looks good to go.
What don't add up? They raised enough money to carry them into 2Q 2015. Companies don't wait until they have 0 cash until they raise money? At a burn rate of 2.2m they will have roughly 4 million in the bank when they do the offering in 2Q 2015, like last offering. Makes good business sense to me to keep emergency money.
Second, nobody said they were doubling the salesforce all in 2Q 2014. It was stated that by end of 2Q 2014 salesforce would be double of that as 2Q 2013.
As far as earnings, it is a "flip of the coin". But I believe we get -.06 EPS as estimated, but we dont get estimate of 1.4 million in revenues. But revenues will be better than 739,000, when EPS was -.08, in Q1 2014 when this stock was trading at 1.25ish going into earnings. How will the stock trade with better revenues than last quarter and better EPS at .95? GLTA
It is actually in clinical chemistry department. Also, 510 K clearances that have clinical data taker longer than those without it. May take 6-12 months. That study you are referring to didn't make any differentiation between those 510ks submitted with data vesus those that didn't.